Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock Holdings Lowered by Meitav Investment House Ltd.

Meitav Investment House Ltd. trimmed its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 37.9% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 39,116 shares of the biopharmaceutical company’s stock after selling 23,884 shares during the quarter. Meitav Investment House Ltd.’s holdings in Halozyme Therapeutics were worth $1,870,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Louisiana State Employees Retirement System boosted its stake in shares of Halozyme Therapeutics by 0.6% during the 4th quarter. Louisiana State Employees Retirement System now owns 35,300 shares of the biopharmaceutical company’s stock worth $1,688,000 after acquiring an additional 200 shares in the last quarter. Verdence Capital Advisors LLC boosted its position in shares of Halozyme Therapeutics by 1.9% in the 3rd quarter. Verdence Capital Advisors LLC now owns 13,232 shares of the biopharmaceutical company’s stock valued at $757,000 after purchasing an additional 252 shares during the period. State of New Jersey Common Pension Fund D increased its stake in Halozyme Therapeutics by 0.6% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 47,663 shares of the biopharmaceutical company’s stock worth $2,279,000 after purchasing an additional 302 shares in the last quarter. Nations Financial Group Inc. IA ADV raised its holdings in Halozyme Therapeutics by 2.4% during the 4th quarter. Nations Financial Group Inc. IA ADV now owns 14,062 shares of the biopharmaceutical company’s stock worth $672,000 after buying an additional 328 shares during the period. Finally, Diversify Advisory Services LLC lifted its stake in Halozyme Therapeutics by 8.5% during the third quarter. Diversify Advisory Services LLC now owns 5,331 shares of the biopharmaceutical company’s stock valued at $305,000 after buying an additional 418 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Analyst Ratings Changes

HALO has been the topic of several research analyst reports. Wells Fargo & Company lowered their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. JMP Securities raised their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research note on Friday, November 1st. Piper Sandler boosted their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. Finally, HC Wainwright raised their price objective on shares of Halozyme Therapeutics from $70.00 to $72.00 and gave the company a “buy” rating in a research report on Wednesday. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $61.11.

Insider Transactions at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 10,000 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the sale, the director now owns 43,611 shares in the company, valued at approximately $2,180,986.11. This trade represents a 18.65 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Price Performance

Shares of Halozyme Therapeutics stock opened at $57.77 on Thursday. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. The firm has a fifty day simple moving average of $53.07 and a 200-day simple moving average of $54.56. The stock has a market capitalization of $7.35 billion, a price-to-earnings ratio of 19.13, a PEG ratio of 0.44 and a beta of 1.25. Halozyme Therapeutics, Inc. has a 1-year low of $35.50 and a 1-year high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 41.43% and a return on equity of 179.82%. The company had revenue of $298.01 million during the quarter, compared to analysts’ expectations of $285.74 million. On average, sell-side analysts expect that Halozyme Therapeutics, Inc. will post 3.87 earnings per share for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.